ARCH Venture Partners — Funding Activity & Portfolio Companies

Activity in this selectionSeries B

ARCH Venture Partners creates and backs companies built on scientific discoveries, with a healthcare focus on technologies that prevent, detect and treat disease.

The firm works through company formation as well as financing, using a network of partners to translate science into an operating business. It sizes capital to the development requirements, with investments ranging from very early commitments to hundreds of millions of dollars per company.

Its long-term model accommodates scientific programmes that need substantial development before commercial scale. Founders and researchers can engage around the creation of a company, rather than waiting until a conventional growth-stage investment case is established.

Sources

Rounds participated in: 7
Confirmed lead rounds: 0
New companies: 7
Funding in participating rounds: $1.1B

By stage

Series B7

By primary sector

Biotech7

By country

United States7

Rounds

7 in this selection

Oct 13

Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B

Participant

Sep 8

Moonwalk Biosciences

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

$70MSeries B

Participant

Jun 24

Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B

Role not disclosed

Jun 10

SonoThera

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed